New target for Alzheimer's disease; MIT study highlights RNA-binding proteins' role in cancer; Broad's Altshuler bound for Vertex;

> A new study published in the Journal of Clinical Investigation suggests that triggering the CXCL10 receptor, CXCR3, contributes to the pathology behind Alzheimer's disease. The research indicates that CXCR3 could be a new target in the field. Release

> An MIT study points to a family of RNA-binding proteins, known as Musashi proteins, may be involved in spurring the proliferation of cancer cells. Release

> A little more than four years ago Thomson Reuters selected David Altshuler, the deputy director and chief academic officer of the legendary Broad Institute as one of the world's "hottest" researchers. And today Vertex ($VRTX) announced that he'll be bringing the heat to the Boston biotech as its new CSO, taking the place of the pioneering Peter Mueller. Story

Suggested Articles

A newfound link between BMAL1, a protein involved in circadian rhythms, and triple-negative breast cancer could point to new treatment strategies.

Combining a DYRK1A inhibitor with popular GLP-1 receptor agonists regenerates insulin-producing beta cells, Mount Sinai scientists found.

Arming a peptide taken from the virus that causes foot-and-mouth disease in cows with the payload tesirine shows promise against pancreatic cancer.